Do Physiotherapy Techniques Improve Posture During Admission for a Chest Infection in Adults With Cystic Fibrosis?

This study has been completed.
Sponsor:
Information provided by:
Royal Brompton & Harefield NHS Foundation Trust
ClinicalTrials.gov Identifier:
NCT00806884
First received: December 10, 2008
Last updated: July 26, 2010
Last verified: December 2008
  Purpose

Hypothesis: The addition of a series of musculoskeletal techniques to normal optimal care for the treatment of a respiratory exacerbation in inpatient adults with cystic fibrosis, will lead to further improvements in pain, posture, sputum clearance, lung function and quality of life.


Condition Intervention
Cystic Fibrosis
Other: Physiotherapy Musculoskeletal Treatment
Other: Control group measurements

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Health Services Research
Official Title: Do Physiotherapy Joint and Muscle Movement (Musculoskeletal) Techniques Improve Posture, Pain, Sputum Clearance, Lung Function or Quality of Life During Admission for a Respiratory Exacerbation in Adults With Cystic Fibrosis?

Resource links provided by NLM:


Further study details as provided by Royal Brompton & Harefield NHS Foundation Trust:

Primary Outcome Measures:
  • Thoracic index as measured by the flexicurve (Boyle, Bradley et al. 2008). [ Time Frame: Day 0 of admission, Days 5,10 & prior to discharge ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Lung function: forced expiratory volume in one second (FEV1), forced vital capacity (FVC) [ Time Frame: Days 0,5,10 & pre discharge ] [ Designated as safety issue: No ]
  • Pain assessment using a 10-centimetre visual analogue scale [ Time Frame: Days 0,5,10 & pre discharge ] [ Designated as safety issue: No ]
  • Sputum weight [ Time Frame: Days 0,5,10 ] [ Designated as safety issue: No ]
  • Ease of sputum clearance using a 10-centimetre visual analogue scale [ Time Frame: Days 0,5,10 & pre discharge ] [ Designated as safety issue: No ]
  • Quality of life - CF-38 questionnaire (Ethics reference number: 98-167) [ Time Frame: Days 0 & pre discharge ] [ Designated as safety issue: No ]
  • Hospital Anxiety and Depression Scale (Zigmond & Snaith 1983) [ Time Frame: Days 0 & pre discharge ] [ Designated as safety issue: No ]

Estimated Enrollment: 50
Study Start Date: June 2008
Study Completion Date: August 2009
Primary Completion Date: August 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: Control Arm1
Normal optimal medical and physiotherapy treatment
Other: Control group measurements
None other than control group measurements
Experimental: Treatment Arm 2
Physiotherapy musculoskeletal interventions in addition to normal optimal medical and physiotherapy care
Other: Physiotherapy Musculoskeletal Treatment
Other: Physiotherapy Musculoskeletal Treatment Specific, gentle oscillatory mobilisations to the rib cage and thoracic spine of the subjects to improve joint alignment and mobility, and to reduce pain. Treatment of specific muscle dysfunction or tight muscle groups to further optimise muscle length and biomechanical relationships in the area , leading to improved efficiency of recruitment and improved power output. Postural education and awareness discussions to improve the subject's own joint alignment and ability in a functional manner. A short programme to reinforce the progress during the treatment sessions may be given.
Other Names:
  • manual therapy
  • Manual techniques
  • physiotherapy joint mobilisations
  • physical therapy joint mobilisations

  Hide Detailed Description

Detailed Description:

Experimental design

A prospective, single blind, randomised control trial.

Methods

50 subjects will be recruited by the admitting physiotherapists from the inpatient wards at Royal Brompton Hospital. Using stratified computer randomisation, the subjects will be allocated to either the control (no treatment group) or the treatment group. The randomisation will be carried out by an independent member of the Department of Cystic Fibrosis and the outcome measures recorded by an observer blind to the randomisation.

Method:

  • Two key investigators will be involved in the study to perform the treatment intervention as outlined in the paragraphs below
  • The subjects' records will be reviewed by the key investigators to ensure they meet the inclusion criteria
  • Prospective subjects will be given written and verbal information about the project and be given 24 hours to consider entry to the study
  • Subjects will give written consent to participate in the project. The top copy will be included in the patient's medical record and a copy placed in the patient's study file
  • A letter will be written to the subject's General Practitioner outlining the purpose of the study and inviting him/her to make contact to discuss the study in more detail if there are any queries or concerns
  • The subjects will be withdrawn if there is a clinical deterioration negating the inclusion criteria or they are discharged for further home intravenous antibiotic treatment
  • Three independent observers (the senior & junior physiotherapists usually working with this patient group) will be trained to ensure good intra & inter-relater reliability in the recording of the measurements

Intervention for the treatment group:

The treatment group will receive the interventions on top of their usual chest physiotherapy and medical care. A treatment series of gentle joint and muscle movements (musculoskeletal interventions) will be undertaken by a physiotherapist, on alternate days for the duration of admission. The physiotherapy musculoskeletal assessment and intervention may last up to 45 minutes on alternate weekdays and may include one or a combination of the following techniques which are documented in populations with postural changes, thoracic stiffness, discomfort and/or pain:

  • Specific, gentle oscillatory mobilisations to the rib cage and thoracic spine of the subjects to improve joint alignment and mobility, and to reduce pain. These techniques should optimise chest wall mechanics, improve the length-tension relationships of the muscles and normalise movement to dysfunctional areas (Maitland, Banks et al. 2001;Mulligan 2005)
  • Treatment of specific muscle dysfunction or tight muscle groups to further optimise muscle length and biomechanical relationships in the area (Massery 2005), leading to improved efficiency of recruitment and improved power output (Travell & Simons 1983)
  • Postural education and awareness discussions to improve the subject's own joint alignment and ability in a functional manner. A short programme to reinforce the progress during the treatment sessions consisting of no more than three specific stretching or strengthening exercises may be given.

Control Group:

The control group will receive their usual medical and physiotherapy management but no placebo intervention.

Data Collection:

The outcome measures will be undertaken by one of three independent observers to pre-agreed protocols, before the first intervention session, and before intervention sessions on day five, day ten and day of discharge. The questionnaires CF-38 and the Hospital Anxiety and Depression Scale will be completed on initiation and completion of the study.

Sample size calculation: The number of patients needed for this study was based on testing of posture before and after musculoskeletal intervention in the outpatient adult cystic fibrosis randomised controlled trial ("Do physiotherapy musculoskeletal techniques improve forced expiratory volume in one second (FEV1) in adults with cystic fibrosis?"; Ethics reference number: 06/Q0404/81). To test for a three point change in thoracic index at the 5% significance level, using a square-root of within-mean standard of error of three would require at least 50 patients to achieve 90% power.

Analysis

Statistical advice was given by Mr Michael Roughton, Statistician, Royal Brompton Hospital and Imperial College London. The data will be analysed using an appropriate test e.g. t-tests or Mann-Whitney tests.

The intra & inter-rater reliability and repeatability of the measurements, by the independent observers, will be determined using Bland Atman plots to ensure they lie within clinically acceptable limits of agreement.

  Eligibility

Ages Eligible for Study:   16 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of cystic fibrosis (genotype or sweat sodium >70 millimoles per litre or sweat chloride of >60 millimoles per litre)
  • 16 years of age or over
  • Inpatient admission for respiratory exacerbation as defined by the Cystic Fibrosis Trust (Cystic Fibrosis Trust Antibiotic Group 2002)
  • Inpatients able to stand for the measurement period without cardiovascular or respiratory compromise.

Exclusion Criteria:

  • Current severe haemoptysis
  • Low bone density (Z score < -3)(World Health Organisation Study Group 1994)
  • Rib fractures
  • Pregnancy
  • Inability to give consent for treatment/ measurement
  • Planned initiation or continuation of treatment in the home environment
  • Current participation in another study.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00806884

Locations
United Kingdom
Royal Brompton Hospital
London, United Kingdom, SW3 6NP
Sponsors and Collaborators
Royal Brompton & Harefield NHS Foundation Trust
Investigators
Principal Investigator: Professor ME Hodson Imperial College London
  More Information

No publications provided

Responsible Party: Professor ME Hodson, Royal Brompton & Harefield NHS Trust
ClinicalTrials.gov Identifier: NCT00806884     History of Changes
Other Study ID Numbers: 08/H0708/25, 2008CF003B
Study First Received: December 10, 2008
Last Updated: July 26, 2010
Health Authority: United Kingdom: National Health Service

Keywords provided by Royal Brompton & Harefield NHS Foundation Trust:
Cystic Fibrosis
Musculoskeletal Physiotherapy
Manual therapy
Posture
Pain

Additional relevant MeSH terms:
Cystic Fibrosis
Fibrosis
Pancreatic Diseases
Digestive System Diseases
Lung Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases
Pathologic Processes

ClinicalTrials.gov processed this record on April 17, 2014